Dear Colleagues,
The 2023 APN Symposium will be held online on November 29-30. While this year's symposium was originally planned for an offline event after the end of the COVID-19 pandemic, due to various circumstances during the preparation process, it will be held as an offline event. We ask for your understanding, and we would like to inform you that next year's symposium will be hosted in Japan as an offline event. Since its inception, APN has invited speakers from over ten APN countries for the annual symposium, with a mission to promote the development of Pharmacometrics in the Asian region and enhance networking opportunities. Through these efforts, the APN Symposium has become a well-established pan-Asian conference in the field of quantitative pharmacology, and we are very proud and pleased about this. This year, we have also invited various speakers from different Asian countries. For information regarding the program and registration (registration period: November 10 ~ 23, JST), please refer to the following link: https://apn-tokyo.jp/ For further details, please contact Dr. Atsunori Kaibara of the Conference Organizing Committee at kaibara_atsun...@lilly.com<mailto:kaibara_atsun...@lilly.com> Thank you. APN Chair Kyungsoo Park --------------------------------------- Kyungsoo Park, PhD, MD Professor of Pharmacology Yonsei University College of Medicine 50-1 Yonsei-Ro, Seoul 03722, Korea Tel +82-2-2228-1735 / Fax +82-2-313-1894 상기 메일은 지정된 수신인 만을 위한 것이며 부정경쟁 방지 및 영업비밀보호에 관한 법률을 포함하여 관련 법령에 따라 보호의 대상이 되는 영업비밀, 산업기술 등을 포함하고 있을 수 있습니다. 본 문서에 포함된 정보의 전부 또는 일부를 무단으로 제3자에게 공개, 배포, 복사 또는 사용하는 것은 엄격히 금지됩니다. 본 메일이 잘못 전송된 경우, 발신인에게 알려주시고 즉시 삭제하여 주시기 바랍니다. The above message is intended solely for the named addressee and may contain trade secret, industrial technology or privileged and confidential information otherwise protected under applicable law including the Unfair Competition Prevention and Trade Secret protection act. Any unauthorized dissemination, distribution, copying or use of the information contained in this communication is strictly prohibited. If you have received this communication in error, please notify the sender by email and delete this communication immediately.
